Desvenlafaxine as a Potential First-Line Treatment for Major Depressive Disorder: A Comprehensive Review and Consensus-Based Clinical Perspective on Efficacy, Safety and Patient Selection Profiles

Abstract

Major depressive disorder is a leading cause of disability worldwide, with significant challenges in treatment response, adherence and functional recovery. Despite the availability of numerous antidepressants, a substantial proportion of patients fail to achieve remission with initial therapy, underscoring the need for effective first-line treatment options. Desvenlafaxine, a serotonin-noradrenaline reuptake inhibitor, has demonstrated efficacy and safety in major depressive disorder, while its pharmacokinetic properties result in minimal drug–drug interactions. This narrative review evaluates clinical evidence supporting the use of desvenlafaxine as a first-line treatment and examines patient subgroups that may benefit most from this antidepressant. A comprehensive literature review was conducted to evaluate the evidence on desvenlafaxine in the treatment of major depressive disorder. This was supplemented by clinical insights discussed during a virtual advisory board meeting held on 16 December, 2024, attended by the authors—psychiatrists from Italy, Germany, Spain, Ireland and Portugal—together with representatives from Neuraxpharm, who market desvenlafaxine. The available evidence suggests that desvenlafaxine offers early symptom relief, sustained efficacy across diverse major depressive disorder symptom clusters, and benefits for patients with anhedonia, fatigue, cognitive dysfunction and functional impairment. Its tolerability and safety profile, including a lower risk of weight gain and drug–drug interactions, contributes to its ease of use and improved adherence. Based on the authors’ clinical consensus, desvenlafaxine may be particularly suitable for working-age adults, perimenopausal and menopausal women, those with general medical comorbidities or polypharmacy concerns, and individuals requiring an antidepressant with a broad mechanism of action. In addition, its predictable pharmacokinetics make it a practical choice in primary care settings. While most current guidelines typically recommend selective serotonin reuptake inhibitors as first-line treatment, the favourable tolerability profile and efficacy of desvenlafaxine across diverse symptom clusters may support its consideration as a first-line option in select patient populations.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40261-026-01576-6.

Plain Language Summary

Depression is a common mental health condition that can seriously impact on a person’s daily life, work and relationships. Many people with depression struggle to find an effective treatment, and even when they do, side effects such as weight gain or sexual dysfunction can make it difficult to continue taking medication. Desvenlafaxine is a type of antidepressant known as a serotonin-noradrenaline reuptake inhibitor. It works by targeting two important chemical pathways in the brain—serotonin and noradrenaline—which help improve depressive symptoms. This article reviews the scientific evidence on how well desvenlafaxine works, how safe it is, and which patients may benefit most from it as a first-choice treatment for depression. This article is based on a review of the existing published literature and clinical insights from a meeting of psychiatry experts from different countries. The findings suggest that desvenlafaxine can provide relief from symptoms of depression early in treatment, is effective for patients with low energy, difficulty concentrating or lack of motivation, and is less likely than some other antidepressants to cause weight gain. Based on the available evidence and the experts’ experience, desvenlafaxine may be particularly useful for patients who take multiple medications as it has a lower risk of interactions with other drugs. While not suitable for everyone, desvenlafaxine may be a valuable option for many people with depression, particularly those who need quick symptom relief, actively employed adults, perimenopausal women, individuals with comorbid physical health conditions, and those who struggle with fatigue and cognitive problems.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40261-026-01576-6.

Key Points

Desvenlafaxine, a serotonin-noradrenaline reuptake inhibitor, has demonstrated efficacy and safety in the management of major depressive disorder.

This article is informed by a comprehensive review of the literature and by clinical insights discussed during an international advisory board meeting involving the authors, which aimed to define the profile of patients most likely to benefit from desvenlafaxine as a first-line treatment for major depressive disorder.

Desvenlafaxine may be particularly well suited for the treatment of patients with anhedonia, fatigue, cognitive dysfunction, polypharmacy, alcohol use, and general medical comorbidities, and for perimenopausal and menopausal women; its predictable pharmacokinetics, rapid onset of action, and ease of use make it a valuable option for both psychiatric and primary care settings.

Introduction

Depression is the most common mental disorder in community settings [1]. The overall point prevalence of depressive disorder in Europe is estimated to be 6.38% [2]. The coronavirus disease 2019 pandemic has further exacerbated the global burden of depression, resulting in an estimated 27.6% increase in cases of major depressive disorder (MDD) worldwide in 2020 [3]. Depression was ranked as the single largest contributor to global disability in 2015, accounting for 7.5% of all years lived with disability [4]. The significant burden of depression is reflected in its impact on social and occupational functioning, physical health and overall quality of life [1]. The effects of depression include substantial economic costs due to lost productivity, increased healthcare utilisation and a higher reliance on social welfare systems [1].

Despite the availability of numerous antidepressant drugs with various mechanisms of action, the treatment of MDD remains a significant challenge [5]. It is estimated that 20–30% of patients with depression do not respond to their first pharmacological treatment, notwithstanding appropriate dosing and duration [1]. Moreover, the likelihood of achieving remission decreases substantially with each line of treatment, from 37% and 31% for first- and second-line treatments, to just 14% and 13% for third- and fourth-line treatments, respectively [6]. The timing of treatment initiation also plays a crucial role in outcomes, as patients with a duration of untreated illness of ≤ 8 weeks are nearly four times more likely to achieve sustained response compared with those with a duration of untreated illness of > 8 weeks [7]. Another major challenge is the high rate of treatment non-adherence, as more than half of patients prescribed antidepressant medication discontinue it within the first 4 months [8]. Concern about adverse effects (AEs) is one of the main reasons for antidepressant discontinuation [9]. Finally, early optimised treatment is critical to achieving full symptomatic and functional recovery in patients with MDD, as the persistence of even mild depressive symptoms after treatment is linked to continued functional impairment and a higher risk of relapse [10]. These challenges highlight the need for novel approaches to the management of MDD, including more refined use of currently available antidepressants.

The choice of antidepressant should be based on patients’ preferences and characteristics (including comorbidities [psychiatric/non-psychiatric]) and concomitant medications, the severity of the depressive episode and the patient’s specific MDD symptoms [11]. Depression can manifest with a variety of symptoms; these may vary in intensity and, to reach criteria for a diagnosis of MDD, must cause the patient distress or significantly impair their functioning [12, 13]. The symptoms of MDD include depressed mood, hopelessness, weight loss or gain, insomnia or hypersomnia, decreased concentration, marked indecisiveness, low self-worth, excessive or inappropriate guilt, and suicidal ideation. Somatic symptoms include psychomotor agitation or retardation, fatigue or lack of energy (anergia/lassitude) and other somatic symptoms (such as pain), diminished or lack of interest/pleasure in activities (anhedonia) and lack of motivation (avolition) [12, 13]. These symptoms can be preferentially addressed by engaging specific neurotransmitter systems in the central nervous system or through the combined modulation of multiple pathways (Fig. 1) [14, 15]. Depressed mood and cognitive dysfunction may be more responsive to treatments that act on all three monoamine neurotransmitters (noradrenaline, serotonin and dopamine). In contrast, anergia may respond better to noradrenergic engagement, anhedonia to dopaminergic engagement, avolition to combined noradrenergic and dopaminergic engagement, and anxiety and irritability to noradrenergic and serotonergic engagement. This complex interaction between neurotransmitters and different domains of MDD suggests that antidepressants targeting different neurotransmitter systems may vary with regard to efficacy for different symptoms, and that a patient’s specific symptom profile should be considered when choosing an antidepressant, particularly as an initial treatment. Moreover, given that it is unclear which neurotransmitter system is (most) disrupted or amenable to treatment response in a given patient, agents targeting multiple neuroreceptor systems may be beneficial.

Fig. 1.

Role of neurotransmitters in the pathogenesis of the symptoms of major depressive disorder.

Adapted from Fig. 1 in Prodan-Bărbulescu et al. Evaluating the connection between microRNAs and long non-coding RNAs for the establishment of the major depressive disorder diagnosis. Biomedicines. 2024;12(3):516. https://doi.org/10.3390/biomedicines12030516 [66], under a CC-BY 4.0 license (creativecommons.org/licenses/by/4.0)

Commonly used and recommended first-line antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and other classes of antidepressant agents such as mirtazapine, bupropion and vortioxetine [11, 16–18]. These drugs vary in their pharmacological profiles, with some acting selectively on a single neurotransmitter system (e.g. SSRIs on the serotonergic system) and others targeting multiple systems simultaneously (e.g. SNRIs on the serotonergic and noradrenergic systems).

Desvenlafaxine is a well-established SNRI [19]. It is approved for the treatment of MDD in several countries and regions, including the USA and Europe [5, 20]. The efficacy and safety of desvenlafaxine have been established in several clinical trials [21–24]. In addition, desvenlafaxine is characterised by linear and uncomplicated pharmacokinetics, and a low likelihood of drug interactions [5, 20].

The objective of this narrative review is to evaluate the evidence on the use of desvenlafaxine in patients with MDD. In addition, we discuss the profiles of patients who may benefit most from receiving desvenlafaxine as first-line therapy for MDD based on the insights gathered during an advisory board meeting.

Methods

In August 2024, the PubMed database was searched (from inception) to identify relevant English-language publications (see ‘Supplementary methods’ in the Electronic Supplementary Material for the search terms and string used). In addition to the initial search, the reference lists of the identified publications were reviewed to capture any additional relevant studies. Furthermore, papers known to be pertinent to the review, as identified by the authors, were also included.

The authors of this article participated in an advisory board meeting held virtually on 16 December, 2024 to discuss the clinical use of desvenlafaxine in the treatment of MDD, together with representatives from Neuraxpharm, who market desvenlafaxine. The panel members were invited based on their extensive clinical experience in managing patients with depression and specific expertise in the use of desvenlafaxine for treating MDD. To ensure diverse perspectives, panellists were chosen from five different European countries, allowing for the integration of insights from varied healthcare systems and practices. This selection process aimed to gather an international group to provide informed recommendations on the potential role of desvenlafaxine as a first-line treatment for MDD. The advisory board aimed to assess the role of desvenlafaxine as a first-line treatment for MDD, focusing on identifying patient subgroups that may benefit from it most; review clinical considerations in antidepressant selection; evaluate efficacy, safety and tolerability data; and discuss the practical application of desvenlafaxine in clinical settings, including primary care. Key discussion points and recommendations from the advisory board were recorded and summarised in meeting minutes. These insights were systematically analysed and incorporated into the article to reflect expert opinion on the role of desvenlafaxine in the first-line treatment of MDD.

Pharmacological Profile of Desvenlafaxine

Mechanism of Action

Desvenlafaxine is a succinate salt monohydrate of O-desmethylvenlafaxine, a major active metabolite of the antidepressant venlafaxine [5, 25], and the prescribed form is a racemic mixture of the R-(–) and S-(+) isomers. Desvenlafaxine is a second-generation antidepressant that inhibits serotonin and noradrenaline reuptake, thereby increasing the concentrations of these neurotransmitters in the synaptic cleft [5, 25]. In addition, desvenlafaxine exhibits a weak inhibitory effect on dopamine reuptake [19, 20].

In vitro studies have demonstrated that the binding affinity of desvenlafaxine for the noradrenaline transporter is three times higher than that of venlafaxine, and that it has a more balanced selectivity for both the noradrenaline and serotonin transporters from the first doses compared with venlafaxine [25]. For example, venlafaxine primarily exhibits serotonergic activity at low doses (typically below 150 mg/day) and engages noradrenergic pathways only at higher doses [26]. Furthermore, desvenlafaxine shows negligible interaction with muscarinic, cholinergic, histaminergic and adrenergic receptors [5, 20].

Pharmacokinetics

Desvenlafaxine has an absolute bioavailability of approximately 80% following oral administration [5]. Once absorbed, desvenlafaxine demonstrates low plasma protein binding (approximately 30%) [5]. Peak plasma concentrations are typically achieved after approximately 7.5 h, which is slightly delayed compared with venlafaxine, whose peak plasma concentration occurs at approximately 5.5 h [27]. The pharmacokinetics of desvenlafaxine are linear, both after single and repeated dosing within the range of 100–900 mg [5]. Desvenlafaxine has a mean terminal half-life of approximately 11 hours (range 8–14 h) [5]. Steady-state plasma concentrations are reached within 4–5 days of once-daily dosing [5]. Although the administration of desvenlafaxine with food can reduce the rate of absorption, it has minimal impact on the overall bioavailability of the drug [5]. Desvenlafaxine is primarily excreted in urine [25].

Desvenlafaxine is minimally metabolised by the hepatic cytochrome P450 (CYP) enzyme system, with less than 5% of the drug being converted to the oxidative metabolite N,O-didesmethylvenlafaxine [20]. This conversion is mediated by CYP3A4 [20]. In addition, desvenlafaxine shows little evidence of interaction with the P-glycoprotein transport protein [28] and there is no direct evidence that is undergoes metabolic isomerisation.

As a result of its minimal metabolism by CYP enzymes such as CYP2D6, desvenlafaxine offers distinct advantages compared with venlafaxine [20]. An open-label crossover study conducted in 14 healthy volunteers found no difference in the peak plasma concentration of desvenlafaxine between extensive and poor CYP2D6 metabolisers [29]. However, the efficacy of venlafaxine is significantly influenced by CYP2D6 metaboliser status, with poor metabolisers of CYP2D6 experiencing lower response and remission rates [30–32]. The fact that there was no difference in dose, AEs and treatment discontinuation between extensive and poor CYP2D6 metabolisers [30] suggests that the lesser conversion to and availability of desvenlafaxine may have contributed to the lower efficacy in the poor metaboliser group.

Desvenlafaxine is available as extended-release tablets of 50 mg or 100 mg, taken orally once a day [25]. The 50-mg dose has been shown to have a therapeutic effect in patients with MDD, reducing the need for titration [33, 34]. In patients with hepatic insufficiency, no dose adjustment is generally required; however, a maximum dose of 100 mg/day is recommended for patients with moderate-to-severe hepatic impairment to avoid potential accumulation of the drug [20]. For patients with renal impairment, the starting dose of 50 mg/day is generally safe; however, it is recommended that patients with severe renal impairment (creatinine clearance < 30 mL/min) take 50 mg every other day [35]. As desvenlafaxine exposure increases with age, owing to the natural decline in renal function, clinicians should consider renal function rather than age alone when determining the appropriate dose in elderly patients [35, 36]. Provided renal function is taken into account, the standard 50-mg/day dose is considered to be safe for elderly patients [35].

Efficacy

As noted in the prescribing information, the recommended dosage of desvenlafaxine is 50 mg/day, but it can be increased to 100 mg/day if needed [37]. While dosages of up to 400 mg/day have been studied and were effective, dosages greater than 50 mg/day do not appear to be associated with markedly greater efficacy and are more likely to be associated with adverse reactions and treatment discontinuation [37]. Therefore, the focus in this section (and those that follow) will be on dosages of desvenlafaxine of 50 and 100 mg/day.

The efficacy of desvenlafaxine has been evaluated in nine short-term, placebo-controlled clinical trials that collectively included 4279 adult outpatients with MDD [5]. Among these, 1714 patients received desvenlafaxine 50 mg, 870 received desvenlafaxine 100 mg and 1695 received placebo. Several pooled analyses of these clinical trials have been conducted [23, 33, 38].

A post hoc meta-analysis of the nine double-blind, placebo-controlled clinical trials (using mixed-effects model for repeated measures) showed that patients receiving desvenlafaxine 50 mg/day experienced significantly greater reductions in the 17-item Hamilton Rating Scale for Depression (HAM-D₁₇) compared with those who received placebo by the end of week 1 (p = 0.0129) and at week 2 (p = 0.0002), an effect that was maintained through to week 8 (p < 0.0001) [33]. In addition, early symptom improvement (i.e. at week 2) significantly predicted remission by week 8 in both treatment groups (p < 0.0001), as assessed by logistic regression analyses [33].

Desvenlafaxine also showed robust antidepressant efficacy across a variety of outcomes in another integrated analysis of the nine clinical trials, which demonstrated that both the 50-mg/day and 100-mg/day doses of desvenlafaxine resulted in statistically significant improvements in depressive symptoms, response rates and remission rates [23]. Specifically, the response rate (defined as a ≥ 50% reduction in HAM-D₁₇ score) at week 8 was significantly higher with desvenlafaxine 100 mg/day compared with placebo (p < 0.0001) [23]. The remission rate (defined as a final HAM-D₁₇ score of ≤ 7) at week 8 was significantly higher with both desvenlafaxine 50 mg/day and 100 mg/day compared with placebo (p < 0.0001).

The comparative efficacy of desvenlafaxine and venlafaxine has been examined in a meta-analysis that used placebo as a common comparator and assessed outcomes at an 8-week endpoint [38]. The pooled weighted mean difference (WMD) for the mean change in HAM-D₁₇ score from baseline was − 2.81 (95% confidence interval [CI] − 3.72 to − 1.91) for desvenlafaxine and -2.61 (95% CI − 3.17 to − 2.05) for venlafaxine, with an indirect Bayesian analysis showing no significant difference between the two drugs (weighted mean difference − 0.27; 95% CI − 1.17 to 0.65) [38]. The mean response rate was 50% for desvenlafaxine and 52% for venlafaxine, while the mean remission rate was 30% for desvenlafaxine and 35% for venlafaxine, with no statistically significant differences between the two treatments [38].

The efficacy of desvenlafaxine (50 mg/day) has also been reported to be comparable with that of another SNRI, duloxetine (60 mg/day) [39]. A randomised, double-blind, non-inferiority trial assessed the efficacy of the two drugs over an 8-week treatment period in 420 patients with MDD. Non-inferiority of desvenlafaxine to duloxetine was demonstrated, with an adjusted least squares mean change from baseline to week 8 in HAM-D₁₇ total score of − 15.3 (95% CI − 17.73 to − 12.89) and − 15.9 (95% CI − 18.44 to − 13.49), respectively. The rate of response was 78.6% in the desvenlafaxine group and 83.0% in the duloxetine group, while the rate of remission was 57.2% and 58.8%, respectively, with no statistically significant differences between the two groups.

A post-hoc pooled analysis of data from nine short-term, randomised, double-blind, placebo-controlled trials of desvenlafaxine in patients with MDD (n = 4279) assessed its impact on energy and lassitude symptoms using data from items related to energy in the HAM-D₁₇ and Montgomery–Åsberg Depression Rating Scale (MADRS) [40]. A statistically significant improvement was seen for all outcomes related to energy/lassitude in desvenlafaxine- versus placebo-treated patients, with some evidence of a dose–response effect (50 mg/day versus 100 mg/day). Early improvement in energy/lassitude symptoms was associated with improved overall depression outcomes (as assessed by HAM-D₁₇ and MADRS scores) at week 8. Another study found that desvenlafaxine improved fatigue and low energy (assessed by self-rated scales; both p < 0.001) in employed adults with MDD (n = 35) [41]. Changes in these symptoms significantly and independently predicted change in some work functioning measures. Standardised regression coefficients indicated that self-reported fatigue and energy measures were as strong as or stronger predictors of functional improvement than changes in overall depression severity for several outcomes. For example, for the total score on the Sheehan Disability Scale, the β coefficient was 0.482 for the change in patient-perceived fatigue, compared with 0.361 for a change in the MADRS total score.

Regarding the cognitive domain, a study found that 8 weeks of treatment with desvenlafaxine (50–100 mg/day) in employed patients with MDD and subjective cognitive difficulties (n = 36) resulted in a large improvement (Cohen’s d = 1.24) in perceived cognition functioning as measured using the British Columbia Cognitive Complaints Inventory, with an associated improvement in self-rated work functioning [42]. Another 12-week placebo-controlled study in 81 employed individuals with MDD who were experiencing functional impairment found that desvenlafaxine (50 mg/day) significantly improved the quality of working memory performance compared with placebo, as assessed by the Cognitive Drug Research system (Cohen’s d = 0.52); conversely, no effects were seen on the power or continuity of attention [43]. However, an open-label study in patients with MDD who had not adequately responded to SSRI treatment showed that desvenlafaxine (flexible dosing, 50–150 mg/day) led to significant moderate-to-large improvements in attention/working memory (Cohen’s d = 0.50), processing speed (Cohen’s d = 0.60), and subjective perception of cognitive deficits (assessed with the 5-item Perceived Deficit Questionnaire; Cohen’s d = 1.67) after 12 weeks, independently of the degree of improvement in depressive symptoms [44].

Desvenlafaxine has been associated with significant improvements in functional outcomes and in specific symptoms that are relevant to patient functioning. A pooled analysis of data from nine registration studies of desvenlafaxine (50–400 mg/day for 8 weeks) in patients with MDD found an improvement in adjusted mean scores from baseline on the HAM-D₁₇ work/activities item that was significantly greater than placebo (p ≤ 0.001) [45]. Several studies have specifically examined the effects of desvenlafaxine treatment in patients with depression currently in the workforce. Among 427 gainfully employed adults with MDD who reported functional impairment at baseline, treatment with desvenlafaxine (50 mg/day for 12 weeks) resulted in greater improvements from baseline compared with placebo in measures of occupational and physical functioning, with a number of these reaching statistical significance (HAM-D₁₇ work/activities item [p = 0.04], HAM-D₁₇ psychomotor retardation factor [p = 0.01], Work and Productivity Activity Impairment questionnaire presenteeism item [p = 0.04]; Fig. 2) [46]. Improvements were also observed in patients presenting with more severe symptoms, in those with lower energy and in patients with anxious depression. Further, improvements from baseline in functional outcomes were highly correlated (Pearson correlation coefficients range from 0.53 to 0.61; p < 0.0001) with an overall change in HAM-D₁₇ total score at the end of treatment. In another study, 36 employed adult outpatients with moderate-to-severe MDD (MADRS ≥ 23) and subjective cognitive complaints received 8 weeks of open-label desvenlafaxine (50–100 mg/day) treatment [47]. Significant improvements were observed in both depressive symptoms and work functioning, with 77% of patients meeting MADRS response criteria and 49% achieving remission. Functional gains included significant improvements in self-reported work productivity, as assessed by the Lam Employment Absence and Productivity Scale (LEAPS) and the World Health Organization Health and Work Performance Questionnaire (HPQ-Overall Work Performance) [both p < 0.001]. Patients who demonstrated clinically significant improvements in cognitive performance exhibited greater improvements in occupational functioning [47].

Fig. 2.

Adjusted mean (± standard error [SE]) change from baseline in functional outcomes at week 12 in employed patients with major depressive disorder and functional impairment who were treated with desvenlafaxine or placebo [46].

Reproduced with permission from Lam et al. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. Int Clin Psychopharmacol. 2014;29(5):239–51. https://doi.org/10.1097/YIC.0000000000000031. HAM-D₁₇ 17-item Hamilton Rating Scale for Depression, MADRS Montgomery–Åsberg Depression Rating Scale, WPAI Work and Productivity Activity Impairment questionnaire

Desvenlafaxine has also been associated with improvements in general well-being, as assessed by the 5-item World Health Organization Well-Being Index (WHO-5) in the pooled analysis of data from the nine registration studies [45]. Significantly greater improvements from baseline to the final evaluation compared with placebo were noted overall (adjusted mean total score 12.7 vs 11.0, respectively; p < 0.001) and on all five items of the WHO-5 (good spirits, calm/relaxed, active/vigorous, fresh/rested and interest). A post hoc analysis of data from a placebo-controlled trial found statistically significant improvements from baseline for desvenlafaxine compared with placebo in 10 of 16 items from the Quality of Life Enjoyment and Satisfaction Questionnaire (p ≤ 0.0441), and that fewer desvenlafaxine- compared with placebo-treated patients had a severe impairment in quality of life after 12 weeks of treatment (46% vs 62%, respectively; p = 0.0024) [48].

The efficacy of desvenlafaxine has further been evaluated in patients with MDD and non-psychiatric comorbidities, including metabolic syndrome and elevated thyroid-stimulating hormone (TSH) levels. A pooled post-hoc analysis of nine short-term, randomised, double-blind, placebo-controlled trials (n = 4279) assessed outcomes across four subgroups defined by the presence or absence of metabolic syndrome and by the baseline TSH level (above vs at or below the median) [49]. Desvenlafaxine 50 mg/day or 100 mg/day was associated with significantly greater reductions in HAM-D₁₇ total scores at week 8 compared with placebo in all four subgroups. Among patients without metabolic syndrome (n = 3308), the adjusted mean difference from placebo was − 1.77 and − 1.99 points for the 50-mg and 100-mg doses, respectively (both p < 0.0001). Among those with metabolic syndrome (n = 971), the corresponding differences were − 1.39 (p = 0.0059) and − 2.16 (p = 0.0024). Similarly, significant improvements were observed in patients with both high (n = 1999) and low (n = 2042) baseline TSH levels, with adjusted mean differences from placebo that ranged from − 1.74 to − 2.15 points (all p ≤ 0.001). Neither metabolic syndrome nor TSH status significantly predicted treatment response or remission, indicating that desvenlafaxine is effective across these clinically relevant subgroups.

Similarly, pooled data from two double-blind, placebo-controlled studies (n = 798) support the efficacy of desvenlafaxine in perimenopausal (n = 252) and postmenopausal (n = 546) women with MDD [50]. Compared with placebo, desvenlafaxine led to significantly greater reductions in depressive symptoms, with adjusted mean HAM-D₁₇ score improvements of − 10.3 with desvenlafaxine versus − 6.5 with placebo in perimenopausal women, and − 10.1 versus − 7.6, respectively, in postmenopausal women (both p < 0.001). Desvenlafaxine was also associated with significant improvements in MADRS and Sheehan Disability Scale total scores, as well as higher rates of response and remission on both HAM-D₁₇ and MADRS in both subgroups.

Overall, the evidence supports desvenlafaxine as an effective and well-tolerated option for MDD, demonstrating positive effects on specific symptoms (such as energy, fatigue and cognition), associated functional and occupational outcomes, and in diverse patient populations, including actively employed individuals, those with general medical comorbidities, and perimenopausal and post-menopausal women.

Safety

Desvenlafaxine has a safety and tolerability profile that is generally favourable and consistent with other SNRIs (Fig. 3) [5]. Adverse effects are most observed during the first week of treatment and are typically mild to moderate in nature. The frequency of AEs is dose related, with higher doses leading to an increased incidence of AEs [5].

Fig. 3.

Incidence of the most relevant adverse events associated with the use of desvenlafaxine, duloxetine, and venlafaxine

In an integrated analysis of nine short-term, randomised, placebo-controlled trials involving 2950 patients, 86.3% of those treated with desvenlafaxine reported AEs compared with 74.5% of those receiving placebo [21]. Nausea was the most common AE, occurring in 31.9% of patients who received desvenlafaxine and 10.5% of patients who received placebo. However, nausea was generally mild to moderate and tended to decrease after the first week of treatment. Overall, 12% of patients who received desvenlafaxine discontinued treatment because of AEs, compared with 3% of those on placebo. However, at the recommended dose of 50 mg/day, the discontinuation rate was much lower at 4%, similar to the rate observed with placebo (3%) [21].

The head-to-head study versus duloxetine noted a lower incidence of treatment-related AEs in the desvenlafaxine group (67.5% vs 83.4% for duloxetine), and that desvenlafaxine had a more favourable safety profile, characterised by a significantly lower incidence of nausea (27.2% vs 48.8%), dizziness (18.0% vs 28.8%), somnolence (8.3% vs 16.1%), dry mouth (7.8% vs 15.1%), constipation (5.8% vs 12.7%), asthenia (4.9% vs 13.7%) and anxiety (1.5% vs 5.9%; p < 0.05 vs duloxetine for all) [39].

A pooled analysis of short-term clinical trials found that the overall incidence of spontaneously reported sexual AEs with desvenlafaxine was relatively low, though not negligible [21]. Among women, decreased libido and anorgasmia were the most commonly reported AEs (1% each), while among men, erectile dysfunction (7%) and delayed ejaculation (5%) were the most frequently reported. A prospective naturalistic study examined sexual tolerability in 72 patients with MDD treated with desvenlafaxine [51]. Among those initiating desvenlafaxine as first-line treatment (n = 27), the incidence of moderate-to-severe sexual dysfunction decreased significantly from 59.2% at baseline to 44.0% after 3 months. Among patients switched to desvenlafaxine from other antidepressants because of a pre-existing sexual dysfunction, its incidence decreased from 93.3 to 75.6%, with significant improvements in sexual desire and orgasmic function [51]. While desvenlafaxine is not devoid of sexual side effects, these findings suggest it may be better tolerated than many other first-line antidepressants in this important tolerability domain.

Weight changes are another important consideration in the tolerability of antidepressants [5]. Desvenlafaxine has been associated with minimal weight changes, both in the short-term and longer-term studies [52]. In short-term trials, desvenlafaxine treatment led to a small but statistically significant mean weight decrease of − 0.82 kg compared with a slight increase of + 0.05 kg in the placebo group. Over longer-term treatment, weight changes were minimal and comparable between desvenlafaxine and placebo, with no clinically significant weight changes observed [52].

Regarding cardiovascular safety, desvenlafaxine has been associated with small but statistically significant increases in systolic and diastolic blood pressure compared with placebo during short-term treatment [53]. However, in a longer-term study lasting 11 months, no significant changes in blood pressure were observed with desvenlafaxine 50 mg/day, indicating that its impact on blood pressure may diminish over time or stabilise with continued use. Finally, desvenlafaxine does not carry warnings related to corrected QT interval prolongation, which is a significant safety concern with some other antidepressants, including venlafaxine. This lack of association with corrected QT prolongation further supports the cardiovascular safety profile of desvenlafaxine and makes it a suitable option for patients who may be at risk for cardiac issues [53].

There is no evidence from clinical trials to suggest that desvenlafaxine causes akathisia. Three cases of desvenlafaxine-induced akathisia have been reported (in abstract form only), but the authors concluded that such extrapyramidal symptoms with desvenlafaxine are extremely rare [54]. The pharmacokinetic profile of desvenlafaxine (limited hepatic metabolism, minimal CYP involvement) and predominantly renal excretion reduce the potential for clinically relevant drug–drug interactions [55–57], suggesting it may be a suitable option for patients with depression and comorbidities such as hepatic impairment, alcohol use disorder, or concurrent treatment with tamoxifen or methadone.

A real-world retrospective multicentre study by Cardoner and colleagues evaluated adherence, persistence and healthcare resource utilisation in patients with MDD treated with desvenlafaxine compared with other SNRIs and SSRIs [58]. The study analysed data from 574 outpatients across mental health and primary care centres, with 187 patients receiving desvenlafaxine and 387 receiving an SSRI or another SNRI. At 12 months, adherence was significantly higher with desvenlafaxine than with SSRIs/SNRIs (67.9% vs 59.9%; odds ratio 1.66; 95% CI 1.07–2.59; p = 0.024), while treatment persistence was also numerically, though not statistically, higher (34.8% vs 26.4%). In addition, the desvenlafaxine group showed a numerically greater response rate (76.5% vs 70.8%) and remission rate (55.9% vs 50.1%), although these differences also did not reach statistical significance. Importantly, healthcare resource utilisation was lower in the desvenlafaxine group, with significantly fewer emergency room visits (17.6% vs 30.0%; p < 0.001) and psychiatric consultations (86.6% vs 94.1%; p < 0.001), suggesting a potential cost benefit. These findings indicate that the favourable safety and tolerability profile of desvenlafaxine, including its low risk of drug–drug interactions and minimal impact on metabolic pathways, may contribute to improved adherence, potentially leading to better long-term treatment outcomes and a reduced healthcare burden [58].

It is important to note though that desvenlafaxine may carry a higher risk of discontinuation symptoms compared with other antidepressants. A systematic review and meta-analysis of 79 studies investigated the incidence of antidepressant discontinuation symptoms in adult patients with depressive or anxiety disorders [59]. Desvenlafaxine and venlafaxine were associated with the highest event rates for both discontinuation symptoms of any severity (event rate 0.40; 95% CI 0.35–0.45) and severe symptoms (event rate 0.056; 95% CI 0.002–0.678). As such, a gradual dose reduction is recommended when discontinuing treatment [37], particularly in individuals with a history of sensitivity to antidepressant discontinuation.

The relationship between antidepressant use and suicidal ideation or completed suicide is difficult to study, in part because suicidality is usually an exclusion criterion in clinical trials of antidepressants and the rarity of suicide. However, there does appear to be a small increased risk of suicidality with antidepressants, particularly those with marked serotonergic properties [60–62] and in younger patients [62]. Indeed, all antidepressants carry a black-box warning regarding a possible increased risk of suicidal thoughts and behaviours in children, adolescents and young adults, and the need to closely monitor for worsening or emergence of such symptoms [37]. Regarding desvenlafaxine specifically, a retrospective analysis of data from nine double-blind, 8-week studies in outpatients with MDD found that 17 (0.93%) of the 1834 patients who had received desvenlafaxine and 8 (0.72%) of 1116 who had received placebo reported possible suicidality-related AEs, and one patient who had received desvenlafaxine died of completed suicide [63]. However, the risk for any class of suicide-related events, including completed suicide or suicide attempt, and the odds of emergence or worsening of suicidality did not differ significantly between desvenlafaxine-treated and placebo-treated patients [64]. Further, an analysis of post-marketing adverse drug event data in the US Food and Drug Administrations’ Adverse Event Reporting System (FAERS) for the years 2017–2023 found that desvenlafaxine was one of only two antidepressants (the other being vilazodone) of the 38 investigated that was associated with a reduced risk of suicidality reporting relative to fluoxetine [64].

Place of Desvenlafaxine in the Management of Major Depressive Disorder (MDD)

The key pharmacological properties of desvenlafaxine and their relevance to patient profiles in MDD are shown in Fig. 4. The advisory board acknowledged that some current guidelines recommend SSRIs as first-line treatment options for MDD [11, 16], although other guidelines do not stipulate a specific drug class as first-line treatment [17, 18]. The experts considered that desvenlafaxine offers several advantages over venlafaxine and other antidepressants [5, 20, 25]. First, desvenlafaxine has a more balanced selectivity for the noradrenergic versus serotonergic transporter compared with venlafaxine [25]. This suggests that noradrenergic activity may be apparent at lower doses of desvenlafaxine, such as those used to initiate treatment (e.g. 50 mg/day), whereas venlafaxine primarily engages noradrenergic pathways only at higher doses [26]. Secondly, desvenlafaxine is minimally metabolised via the CYP enzyme system, particularly CYP2D6. Unlike venlafaxine, which undergoes extensive hepatic metabolism, desvenlafaxine is largely excreted unchanged, resulting in more predictable pharmacokinetics and a lower risk of drug–drug interactions [5, 20, 25]. Thirdly, desvenlafaxine is distinguished by its favourable tolerability profile, including a lower incidence of common AEs associated with antidepressant treatment, such as sexual dysfunction and weight gain [5, 20, 25]. Given that these AEs are major reasons for treatment discontinuation, the tolerability of desvenlafaxine may contribute to better adherence in long-term treatment. Fourthly, desvenlafaxine is known for its rapid onset of therapeutic action, with noticeable symptom relief often occurring within the first week of treatment—an early response that can be predictive of subsequent remission [33]. Fifthly, clinical observations and prior studies suggest that fatigue, low energy and cognitive impairment may be domains particularly responsive to treatment with desvenlafaxine. Improvements in these areas have been associated with greater functional and occupational recovery in some studies [41, 47]. Finally, unlike some other antidepressants, desvenlafaxine does not require titration for most patients, as its therapeutic effect is often achieved at the standard 50-mg/day dose. This simplifies dosing, reduces the burden of frequent dose adjustments and may improve early treatment adherence. Nevertheless, higher doses of up to 200 mg/day can be considered in the case of insufficient response or residual symptoms.

Fig. 4.

Key pharmacological properties of desvenlafaxine and their relevance to patient profiles in major depressive disorder. AEs adverse events, CYP cytochrome P450

Given its pharmacological and clinical characteristics, the board noted that desvenlafaxine may be particularly appropriate for patients with moderate-to-severe MDD who require a rapid onset of therapeutic action, those with or without comorbid anxiety, those at risk of discontinuing antidepressant treatment, patients taking multiple medications or living with non-psychiatric comorbidities, and patients with hepatic impairment [5, 20, 25]. Anhedonia, fatigue and cognitive dysfunction were identified as characteristic symptoms for which desvenlafaxine may be particularly effective. The experts’ clinical experience suggests that the additional noradrenergic effects of desvenlafaxine contribute to improvements in energy levels, motivation and cognitive processing, which are key for functional recovery. These benefits position desvenlafaxine as a valuable option for working-age adults and individuals whose occupational or daily functioning is impaired by MDD.

Evidence has also demonstrated efficacy of desvenlafaxine in MDD with elevated levels of anxiety [65]. Despite common concerns about noradrenergic activation, especially in patients with comorbid anxiety, the advisory board noted that in their clinical experience, desvenlafaxine is also generally well tolerated in this population. However, in patients with prominent obsessive or ruminative symptoms, SSRIs may still be preferred.

One of the key advantages of desvenlafaxine is its minimal metabolism by CYP450 enzymes, particularly CYP2D6, which makes it a safer choice for patients taking multiple medications. The advisory board highlighted that a significant proportion of patients with depression fall into this category, including those with metabolic syndrome, cardiovascular disease, hepatic impairment and renal impairment. In these patients, desvenlafaxine reduces the risk of drug–drug interactions, an important consideration in both psychiatric and primary care settings.

Based on the authors’ clinical experience and discussion during the advisory board meeting, patients with coexisting alcohol use were identified as another subgroup for whom desvenlafaxine may be a suitable first-line treatment. Although heavy alcohol use remains a contraindication for most antidepressants, MDD comorbid with substance use should not go untreated. Based on the authors’ consensus during the advisory board discussion, the predictable metabolism and reduced drug–drug interactions of desvenlafaxine make it a reasonable option for patients with moderate alcohol consumption who require effective depression management.

The advisory board highlighted that perimenopausal women represent another important group who may benefit from desvenlafaxine as a first-line treatment option. The lower risk of weight gain and favourable tolerability profile may improve adherence in this population, where concerns about hormonal fluctuations, mood instability and weight gain often influence treatment choices.

The rapid onset of action of desvenlafaxine, with noticeable symptom relief within 1–2 weeks, was noted by the advisory board as an advantage in patients who require a fast-acting antidepressant. This is relevant for patients concerned about prolonged symptom burden and for working professionals seeking early improvements in motivation and cognitive function, including younger patients.

The authors also discussed the role of desvenlafaxine in primary care. Given its ease of use, absence of a titration phase and predictable pharmacokinetics, desvenlafaxine was considered a practical choice for general practitioners managing depression. In particular, it was identified as an ideal option for older adults with medical comorbidities, younger patients needing a fast response with minimal side effects and individuals with polypharmacy concerns. In addition, its lack of required dose adjustment for hepatic impairment and minimal adjustment for severe renal impairment makes it a suitable choice for patients with organ dysfunction, who often require careful medication selection to avoid complications.

The advisory board provided several practical recommendations for clinicians prescribing desvenlafaxine. Although previous studies have reported low rates of treatment-emergent hypertension and generally small but statistically significant increases in blood pressure [53], regular monitoring of blood pressure is advised, especially in patients with a history of inadequately controlled hypertension.

Finally, the authors agreed that although discontinuation symptoms may be more common and severe with desvenlafaxine compared with some other antidepressants, they generally can be safely managed through proactive patient communication and a carefully planned tapering strategy. Providing patients with information about the potential for withdrawal symptoms prior to initiating treatment, along with reassurance in advance, can significantly reduce their impact should these symptoms emerge. This approach helps prevent unnecessary distress by establishing appropriate expectations. When discontinuing desvenlafaxine, a slow taper is advisable, and in some cases may involve alternate-day dosing.

Conclusions

For patients with MDD, careful selection of the first-line antidepressant is crucial and should be based on factors such as clinical features, comorbidities, previous treatment response, tolerability and patient preferences. The unique pharmacological profile and clinical benefits of desvenlafaxine position it as a practical, effective and well-tolerated antidepressant for a wide range of patients. Desvenlafaxine may be particularly appropriate for the treatment of patients with anhedonia, fatigue, cognitive dysfunction, polypharmacy, alcohol use and non-psychiatric comorbidities, and perimenopausal and menopausal women. In addition, its predictable pharmacokinetics, rapid onset of action and ease of use make it a valuable option for both psychiatric and primary care settings.

Supplementary Information

Below is the link to the electronic supplementary material.

Funding

This work and the open access publishing fee were funded by Neuraxpharm. The views and conclusions expressed in this article are those of the authors and do not necessarily reflect the views of the funder.

Declarations

Conflict of interest

Claudia Carmassi has been a continuing medical education speaker and/or a consultant or advisor to and/or has received honoraria from Angelini, Lundbeck, Gedeon Richter, Neuraxpharm, Teva Italia and Viatris. Christoph Correll has been a consultant and/or advisor to or has received honoraria from AbbVie, Alkermes, Allergan, Angelini, Aristo, Autobahn, Boehringer Ingelheim, Bristol Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Draig, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, GH, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink Global, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Neurosterix, NeuShen, Newron, Noven, Novo Nordisk, Orion Pharma, Otsuka, PPD Biotech, Recognify Life Science, Recordati, Relmada, Response Pharmaeutical, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Janssen, Lundbeck, Neurocrine and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva and Rovi. He has received grant support from Boehringer Ingelheim, Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, MedLink Global, Mindpax, Quantic and Terran. Javier de Diego-Adeliño has received grants from the Spanish Ministry of Health Instituto de Salud Carlos III (PI23/00469) and from the Fundació La Marató de TV3 (202207-31) and has served as an advisor or continuing medical education speaker for Neuraxpharm, Johnson & Johnson, Lundbeck, Pfizer, Esteve, Viatris and Amgen. Antonio Vian-Lains has served as an advisor or continuing medical education speaker for Neuraxpharm, Johnson & Johnson and Lundbeck. Ciro Oliveira has received honoraria from Angelini Pharma Portugal, AstraZeneca, Bial, GlaxoSmithKline, Jaba Recordati, Johnson & Johnson, Lundbeck, Neuraxpharm and Rovi SA. Vikas Mohan Sharma and Alex Schneider-Pérez are full-time employees of Neuraxpharm.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Author contributions

All authors equally contributed to the development of this manuscript by reviewing the relevant literature in preparation for the advisory board meeting, participated in discussions during the meeting and contributed to the interpretation of evidence. All authors reviewed, provided critical comments on and approved the drafts of the manuscript, approved the final version for publication and agree to be accountable for the work.